EP3778567A1 — Crystalline eravacycline bis-hydrochloride
Assigned to Sandoz AG · Expires 2021-02-17 · 5y expired
What this patent protects
The invention relates to a lyophilized pharmaceutical composition intended for parenteral use comprising eravacycline, wherein the pharmaceutical composition is obtainable or obtained by using crystalline eravacycline bis-hydrochloride, at least one stabilizer selected from sugar…
USPTO Abstract
The invention relates to a lyophilized pharmaceutical composition intended for parenteral use comprising eravacycline, wherein the pharmaceutical composition is obtainable or obtained by using crystalline eravacycline bis-hydrochloride, at least one stabilizer selected from sugars and/or sugar alcohols and at least one acid or base. The pharmaceutical composition of the present invention can be used as medicaments, in particular for treatment and/ or prevention of bacterial infections e.g. caused by Gram negative pathogens or Gram positive pathogens, in particular caused by multidrug resistant Gram negative pathogens. The pharmaceutical composition of the present invention can thus be used as medicaments for e.g. the treatment of complicated intra-abdominal and urinary tract infection
Drugs covered by this patent
- Xerava (ERAVACYCLINE DIHYDROCHLORIDE) · Tetraphase Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.